A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer

Overview of attention for article published in Breast Cancer Research, January 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (87th percentile)
High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

news: 1 news outlet
twitter: 4 X users

patent: 1 patent

Citations

dimensions_citation: 66 Dimensions

Readers on

mendeley: 65 Mendeley

Summary News X Patents Dimensions citations

So far, Altmetric has seen 1 patent that references this research output.

CXCL8 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF FOR USE IN THE TREATMENT OF CANCER-R…

Application WO-2021165510-A1

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.